Introduction
HIV is a mucosal pathogen, and AIDS-associated diarrhea and wasting syndromes were documented during the earliest years of the epidemic [1, 2] . The dramatic depletion of CD4 þ T-cells in the gastrointestinal lamina propria was described in the mid-1990s [3, 4] . Similar findings were reported in simian immunodeficiency virus (SIV)-infected macaques, and it soon became clear that a precipitous decline in mucosal CD4 þ T-cells accompanied acute infection [5] [6] [7] . A resurgence of interest in this area has led to a number of studies designed to characterize host-pathogen interactions in the gastrointestinal and genitourinary tracts, and elucidate the role of mucosal immunity in controlling HIV. This review focuses on recently published work in the field of mucosal immunology as it relates to HIV/SIV infection.
New insights on acute HIV/SIV infection: a proinflammatory cascade leads to rapid viral dissemination 10 days postinfection. An early increase in expression of MIP-3a (CCL20) was associated with an influx of CD123 þ plasmacytoid dendritic cells (pDC). These cells secreted chemokines (MIP-1a/CCL3 and MIP-1b/ CCL4), attracting CCR5 þ CD4 þ T-cells to the endocervix and leading to broad dissemination of infection. To date, similar studies of acute intra-rectal infection have not been reported.
Surprisingly, this work revealed that spreading of infection beyond the site of transmission could be interrupted by administration of an anti-inflammatory compound, glycerol monolaurate (GML) to the cervicovaginal mucosa. GML-treated macaques were completely protected from high-dose mucosal challenge with SIVmac. Thus, a naturally occurring compound can provide protection from mucosal exposure simply by inhibiting immune activation and cytokine/chemokine production [10 ].
Location, location, location: in-vivo E : T ratio predicts viral persistence
Previous studies have suggested that mucosal HIV/SIVspecific cytotoxic T-cells (CTL) are elicited 'too little and too late' [11] . Li and colleagues [12 ] used a combination of in-situ hybridization and MHC class I tetramer staining, termed 'in-situ tetramer/hybridization' (ISTH), to quantify infected cells and SIV-specific CTL in mucosal tissues. Significant reductions in viral load during early infection were associated with E : T ratios of at least 100 : 1 in the female reproductive tract. The authors also studied a well established system of acute vs. persistent infection: lymphocytic choriomeningitis virus (LCMV) [12 ] . The Armstrong strain of LCMV is cleared without causing disease, whereas clone 13 induces persistent viremia. Notably, when ISTH was used to evaluate in-vivo E : T ratios, the Armstrong strain induced a ratio of 40 : 1 in spleen by 8 days postinfection. Although clone 13 also elicited CTL, the effective E : T ratio in tissues was less than 1 : 1. Thus, in both SIVmac and LCMV infections, in-vivo E : T ratio during acute infection was inversely related to the establishment of persistent infection. The authors concluded that a vaccine capable of eliciting a cell-mediated immune response near the portal of entry 'enough and soon enough' might prevent viral dissemination [12 ] ( Fig. 1a ).
Do mucosal T-cell responses matter during chronic HIV infection?
If HIV is analogous to LCMV clone 13, and the acute phase CTL response is 'too little and too late', then does a mucosal CTL response during chronic infection matter, or is it irrelevant? Two studies revealed that Gag-specific rectal CD8 þ T-cell responses in chronically infected individuals were positively associated with CD4 cell count, and inversely related to plasma viral load [13, 14 ] . There was also an association between polyfunctional rectal Gag-specific CD8 þ T-cell responses, lower plasma viral load, and higher blood CD4 cell count. Unfortunately, cross-sectional studies cannot conclusively demonstrate a protective role for these responses, so it is also possible that robust CD8 þ T-cell responses are a consequence of CD4 þ T-cell preservation and relatively low viremia.
Nevertheless, a contribution of mucosal responses to immune control is suggested by studies measuring rectal CD8 þ T-cell responses in 28 individuals who control HIV without therapy (i.e. 'controllers'). Ferre and colleagues [15 ] found that polyfunctional Gag-specific CD8 þ Tcells were significantly more abundant in rectal mucosa from controllers as compared with noncontrollers and patients on ART. Controllers also had relative preservation of rectal CD4 þ T-cells as compared to other HIVinfected groups [15 ] .
Although T-cell responses in HIV controllers can be robust, the vast majority of infected individuals do not effectively control HIV. Gut CD8 þ T-cells from patients with chronic HIV infection, or uninfected controls, contain very low levels of perforin [16, 17] . Because gut perforin expression is increased in inflammatory conditions [18, 19] , this adaptation may limit inappropriate 'friendly fire' that could lead to epithelial damage [16, 19] . However, it might also reduce the ability of mucosal CD8 þ T-cells to clear infection. Furthermore, CD8 þ T-cells in lymph nodes and gastrointestinal mucosa of infected macaques express high levels of PD-1, suggesting immune exhaustion [20] . Together, these findings suggest that the mucosal CD8 þ T-cell response to chronic HIV/SIV infection may be inadequate in most cases ( Fig. 1b ).
An intriguing study suggested that damage to gut epithelium triggers CD8 þ T-cell dysfunction by mediating ligation of the inhibitory receptor KLRG-1 by E-cadherin [21 ] . In HIV-infected patients, increased levels of soluble E-cadherin, an adherens junction protein, are detected in plasma, and the protein shows abnormal distribution in intestinal mucosa. In in-vitro assays, HIV-specific CD8 þ T-cell function was reduced in the presence of soluble E-cadherin. Of note, this study did not assess the function of CD8 þ T-cells isolated from the gastrointestinal tract; instead, assays were performed using peripheral blood mononuclear cell (PBMC) with or without addition of E-cadherin.
Does a mucosal trafficking marker target CD4 T-cells for HIV infection?
Within the past several years, it has become clear that lymphocytes primed in mucosal inductive sites Immune responses to HIV and SIV in mucosal tissues Shacklett 129 are 'instructed' to express antigens that direct homing to mucosal effector sites. Intestinal APC synthesize retinoic acid, which 'instructs' newly primed lymphocytes to express a 4 b 7 integrin [22] [23] [24] . Integrin a 4 b 7 mediates intestinal trafficking by interacting with mucosal addressin cell adhesion molecule-1 (MAdCAM-1), expressed on venules in the lamina propria. Intriguingly, a 4 b 7 may also play a unique role in HIV infection, as activated a 4 b 7 heterodimer can bind gp120 on infected CD4 þ T-cells [25 ] . The gp120-a 4 b 7 interaction, in turn, triggers activation of a L b 7 integrin (LFA-1) on the CD4 þ T-cell surface. Because LFA-1 facilitates cell-cell interactions, its up-regulation on infected cells may facilitate viral transfer to uninfected cells [25 ] . Furthermore, most Th17 cells express a 4 b 7 ; this finding could explain their preferential infection and depletion during acute infection [26 ] . The balance between Th17 and regulatory T-cells may be critical in determining immune activation 'set point'; this topic is reviewed elsewhere in this journal issue.
Another study revealed that the loss of b 7 high cells in blood during SIV infection closely parallels the depletion of lamina propria CD4 þ T-cells [27] . This situation suggests that the frequency of b 7 high CD4 þ T-cells in blood may be used as a surrogate marker to estimate loss or restoration of intestinal CD4 þ T-cells, without the need for gut biopsy. It remains to be determined whether expression of the same marker on blood CD8 þ T-cells can adequately substitute for the direct measurement of HIV-specific CD8 þ T-cell responses in the gastrointestinal tract.
Mucosal B-cells and HIV: polyclonal activation, neutralizing IgA, and Trojan horses
For many years it has been known that HIV infection leads to destruction of the follicular dendritic cell network and involution of germinal centers. However, a recent study investigated B-cells in blood and terminal ileum from patients in acute/early infection [28 ] . HIV infection rapidly induced polyclonal activation of B-cells in blood and gut, including those specific for influenza and autoantigens. Ileal Peyer's patches exhibited loss of germinal centers, and over 80% of follicles contained apoptotic T-and/or B-cells. Although not unexpected, these findings confirm that rapid and profound damage occurs to mucosal inductive sites during acute HIV infection, with important consequences for B-cell differentiation and antibody production.
The issue of 'protective' mucosal antibodies in highly exposed, persistently seronegative (HEPS) individuals remains controversial [29] . Although HEPS by definition lack circulating IgG antibodies specific for HIV, several studies have reported HIV-specific IgA in plasma or mucosal secretions from HEPS [30] [31] [32] [33] [34] [35] [36] (Fig. 1a) . In some cases these antibodies have been found to neutralize HIV infectivity in vitro [37, 38] and/or to inhibit viral transcytosis across an epithelial monolayer [35, 39] . However, other studies have failed to detect such antibodies [40] [41] [42] .
A recent study described the construction of a Fab library from cervical B-cells of HEPS women, from which IgAs specific for gp41 were obtained [43 ] . These antibodies blocked transcytosis of X4 and R5 HIV, and neutralized infectivity in vitro. Intriguingly, a Fab of subtype IgA1 (Fab 43) specific for the gp41 membrane-proximal region showed an unusually long CDR3 region, similar to those described for broadly neutralizing IgG antibodies. Fab 43 also showed evidence of hypermutation, suggesting affinity maturation during prolonged exposure to antigen [43 ] . Given the controversies that persist in this field, it will be important to confirm these potentially exciting findings.
Is Nef a 'Trojan horse' to block class-switching and evade mucosal antibodies? Several years ago, it was reported that HIV Nef can perturb B-cell signaling and blocking class-switching recombination [44] (Fig. 1b) . The initial study did not provide a mechanism by which Nef could enter B-cells in vivo. However, a follow-up study revealed that Nef may utilize intercellular 'bridges' to enter B-cells, which are not typically infected by HIV [45 ]. In lymphoid tissues, including Peyer's patches, B-cells and macrophages are in close proximity and actin-driven cellular conduits form, apparently as a normal intercellular communication network that is 'hijacked' by Nef. Accumulation of Nef in germinal centers was associated with decreased expression of activation-induced cytidine deaminase (AID). The presence of Nef inhibited class switching to IgA and IgG2, and individuals harboring DNef viruses had higher levels of these subclasses in plasma than patients infected with wild-type HIV [45 ] . Interestingly, CD40-independent class switching outside of germinal centers was increased in HIV-infected patients, probably contributing to nonspecific hypergammaglobulinemia.
Can mucosal CD4 R T-cells and epithelial integrity be reconstituted with highly active antiretroviral therapy?
Estes and colleagues [46] previously established that immune activation in HIV/SIV infection is associated with disruption of lymphoid tissue architecture and deposition of collagen in lymph nodes, potentially limiting CD4 þ T-cell repopulation after antiretroviral therapy (ART). Recently, these authors reported that CD4 þ T-cell depletion in ileal Peyer's patches is accompanied by even more extensive collagen deposition than in lymph nodes [47 ] . ART begun during early infection led to an increase in CD4 þ central memory cells in Peyer's patches, but did not restore effector memory cells in the ileal lamina propria. Initiation of ART during chronic infection did not significantly increase CD4 þ Tcells in gut inductive or effector sites. These findings strongly suggest that fibrotic damage severely disrupts Immune responses to HIV and SIV in mucosal tissues Shacklett 131 the ability of gut-associated lymphoid tissue (GALT) to support normal T-cell trafficking and survival, even following ART (Fig. 1b ).
Not only do CD4 þ T-cells fail to fully repopulate the gastrointestinal tract following ART, but recent work suggests that HIV proviral DNA persists in CD4 þ T-cells from terminal ileum following up to 9.9 years of effective therapy [48 ] . Viral envelope (C2-V5) sequences were determined from three sources: resting blood CD4 þ T-cells, activated blood CD4 þ T-cells, and ileal CD4 þ T-cells. Results revealed that viral DNA sequences from these three sources were not significantly different, suggesting ongoing 'cross-seeding' of blood and GALT CD4 þ T-cells, rather than sequence compartmentalization between anatomical sites [48 ] .
On an encouraging note, a study of 23 HIV-positive patients on long-term ART with durable viral suppression revealed CD4 þ T-cell reconstitution in sigmoid colon to levels statistically equivalent to healthy controls [49 ] . Unfortunately, the extent of repopulation in terminal ileum of these patients is unknown. It remains to be determined whether the differences in outcome between this and the previously cited study are related to the sites sampled (i.e. lower vs. upper gastrointestinal tract) or other factors.
Macal and colleagues [50 ] analyzed jejunal biopsies from 14 patients on long-term ART, of whom six had minimal restoration and eight had jejunal CD4 þ T-cell percentages comparable to uninfected controls. Notably, several patients had detectable proviral DNA in mucosa despite undetectable plasma viremia. Relative gut CD4 þ T-cell restoration was associated with higher percentages of CD4 þ central memory cells and Th17 cells in jejunal mucosa, and with polyfunctional HIV-specific CD4 þ T-cell responses in some patients [50 ] . These findings demonstrate that immune responses to HIV and other pathogens can be partially restored in jejunal mucosa following ART.
The effects of suppressive ART on gut epithelial damage were assessed in a study that evaluated electrophysiological properties, mannitol permeability, villus/ crypt ratio, apoptosis and tight junction proteins in jejunal mucosa [51 ] . Untreated HIV-positive patients showed significant impairment as compared to healthy controls; however, findings in ART-treated patients were statistically equivalent to controls. These authors also measured cytokine production in jejunal biopsies, found increased TNFa, IL-2 and IL-4 in untreated HIV-positive patients, and hypothesized that TNFa overproduction may be responsible for the impaired epithelial function observed in untreated infection [51 ] .
In summary, these studies reveal that partial restoration of gastrointestinal CD4 þ T-cells is possible in patients on long-term ART. Restoration appears to be impeded by factors contributing to immune activation and/or collagen deposition, and enhanced by durable control of viral replication. Additional studies are needed to fully assess differences in reconstitution between inductive vs. effector sites, and upper vs. lower gastrointestinal tract.
Conclusion
Recent studies have highlighted the importance of mucosal defenses in determining the host-pathogen balance. Curbing immune activation at the site of transmission may abrogate viral dissemination, and the in-vivo E : T ratio near the site of initial infection may also be critical in limiting viral persistence. Individuals who control HIV without therapy have unusually strong HIV-specific T-cell responses in mucosal tissues, which may limit viral replication during chronic infection. Mucosal B-cell responses are compromised by events occurring during acute infection and class-switching may be impaired by a Nef-mediated mechanism. Finally, at least partial restoration of gut CD4 þ T-cells, barrier function, and mucosal T-cell function is possible in patients on suppressive ART.
How effectively these concepts will be translated into microbicide, vaccine, and/or immunotherapeutic approaches remains to be seen. Several gaps remain to be filled, including elucidation of the early stages of acute infection following rectal transmission; systematic comparison of the effects of HIV/SIV on the upper vs. lower gastrointestinal tract; and detailed study of immune defenses in the male and female reproductive tracts.
